ImmunoGen Files IND for Its HuC242-DM4 Targeted Anticancer Compound

ImmunoGen has submitted an investigational new drug application to the FDA for its huC242-DM4 targeted anticancer therapeutic.

HuC242-DM4 -- a Tumor-Activated Prodrug compound -- is in development by the company for the treatment of CanAg-expressing cancers, such as gastrointestinal and non-small cell lung cancers. The compound is wholly owned by ImmunoGen.